Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Yttrium-90 Radiolabeled Daclizumab, An Anti-CD25 Monoclonal Antibody, Provides Effective Therapy for Refractory and Relapsed Hodgkin's Lymphoma,

Blood (2011) 118 (21): 3706.

https://doi.org/10.1182/blood.V118.21.3706.3706

Published: 2011

Journal Articles

Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome May Be Significantly Improved by the Addition of Rituximab to Dose-Adjusted (DA)-EPOCH and Obviates the Need for Radiation: Results from a Prospective Study of 44 Patients.

Kieron Dunleavy, MD, Stefania Pittaluga, MD, John Janik, MD, Nicole Grant, MPH, Margaret Shovlin, RN, Seth Steinberg, PhD, Mark Raffeld, MD, Louis Staudt, MD, PhD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD, PhD

Blood (2006) 108 (11): 209.

https://doi.org/10.1182/blood.V108.11.209.209

Published: 2006

Journal Articles

DA-EPOCH-R Is Highly Effective in Both BCL-6+ and BCL-6− Untreated De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Study Update and Analysis of Survival Outcomes for Multiple Biomarkers.

Wyndham H. Wilson, MD, PhD, Kieron Dunleavy, MD, Stefania Pittaluga, MD, Nicole Grant, MPH, Margaret Shovlin, RN, Seth Steinberg, PhD, Mark Raffeld, MD, Louis Staudt, MD, PhD, Elaine S. Jaffe, MD, John Janik, MD

Blood (2006) 108 (11): 206.

https://doi.org/10.1182/blood.V108.11.206.206

Published: 2006

Journal Articles

Novel Treatment of Burkitt Lymphoma with Dose-Adjusted EPOCH-Rituximab: Preliminary Results Showing Excellent Outcome.

Kieron Dunleavy, MD, Stefania Pittaluga, MD, John Janik, MD, Nicole Grant, MPH, Margaret Shovlin, RN, Richard Little, MD, Robert Yarchoan, MD, Seth Steinberg, PhD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD, PhD

Blood (2006) 108 (11): 2736.

https://doi.org/10.1182/blood.V108.11.2736.2736

Published: 2006

Journal Articles

Abbreviated Treatment with EPOCH-Rituximab and HAART Suspension Is Highly Effective in AIDS-Related Lymphoma (ARL).

Kieron Dunleavy, MD, Alan S. Wayne, MD, Richard Little, MD, Nicole Grant, MPH, Seth Steinberg, PhD, Elaine S. Jaffe, MD, Stefania Pittaluga, MD, Robert Yarchoan, MD, Jorge Carrasquillo, MD, John Janik, MD, Wyndham H. Wilson, MD, PhD

Blood (2006) 108 (11): 2740.

https://doi.org/10.1182/blood.V108.11.2740.2740

Published: 2006

Journal Articles

Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome Is Significantly Improved by the Addition of Rituximab to Dose Adjusted (DA)-EPOCH and Overcomes the Need for Radiation.

Kieron Dunleavy, MD, Stefania Pittaluga, MD, John Janik, MD, Nicole Grant, RN, Seth Steinberg, PhD, Louis Staudt, MD, PhD, Elaine Jaffe, MD, Wyndham H. Wilson, MD, PhD

Blood (2005) 106 (11): 929.

https://doi.org/10.1182/blood.V106.11.929.929

Published: 2005

Journal Articles

The Addition of Rituximab to Dose-Adjusted EPOCH with HAART Suspension Is Highly Effective and Tolerable in AIDS-Related Lymphoma (ARL) and Allows the Delivery of Abbreviated Chemotherapy.

Kieron Dunleavy, MD, Alan Wayne, M.D, Richard Little, M.D, Nicole Grant, M.P.H., Seth Steinberg, Ph.D, Elaine S. Jaffe, MD, Stefania Pittaluga, MD, Robert Yarchoan, MD, Jorge Carrasquillo, MD, John Janik, MD, Wyndham H. Wilson, MD, PhD

Blood (2005) 106 (11): 930.

https://doi.org/10.1182/blood.V106.11.930.930

Published: 2005

NARROW

Yttrium-90 Radiolabeled Daclizumab, An Anti-CD25 Monoclonal Antibody, Provides Effective Therapy for Refractory and Relapsed Hodgkin's Lymphoma,

Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome May Be Significantly Improved by the Addition of Rituximab to Dose-Adjusted (DA)-EPOCH and Obviates the Need for Radiation: Results from a Prospective Study of 44 Patients.

DA-EPOCH-R Is Highly Effective in Both BCL-6+ and BCL-6− Untreated De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Study Update and Analysis of Survival Outcomes for Multiple Biomarkers.

Novel Treatment of Burkitt Lymphoma with Dose-Adjusted EPOCH-Rituximab: Preliminary Results Showing Excellent Outcome.

Abbreviated Treatment with EPOCH-Rituximab and HAART Suspension Is Highly Effective in AIDS-Related Lymphoma (ARL).

Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome Is Significantly Improved by the Addition of Rituximab to Dose Adjusted (DA)-EPOCH and Overcomes the Need for Radiation.

The Addition of Rituximab to Dose-Adjusted EPOCH with HAART Suspension Is Highly Effective and Tolerable in AIDS-Related Lymphoma (ARL) and Allows the Delivery of Abbreviated Chemotherapy.

Email alerts

ASH Publications

American Society of Hematology

Yttrium-90 Radiolabeled Daclizumab, An Anti-CD25 Monoclonal Antibody, Provides Effective Therapy for Refractory and Relapsed Hodgkin's Lymphoma,

Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome May Be Significantly Improved by the Addition of Rituximab to Dose-Adjusted (DA)-EPOCH and Obviates the Need for Radiation: Results from a Prospective Study of 44 Patients.

DA-EPOCH-R Is Highly Effective in Both BCL-6+ and BCL-6− Untreated De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Study Update and Analysis of Survival Outcomes for Multiple Biomarkers.

Novel Treatment of Burkitt Lymphoma with Dose-Adjusted EPOCH-Rituximab: Preliminary Results Showing Excellent Outcome.

Abbreviated Treatment with EPOCH-Rituximab and HAART Suspension Is Highly Effective in AIDS-Related Lymphoma (ARL).

Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome Is Significantly Improved by the Addition of Rituximab to Dose Adjusted (DA)-EPOCH and Overcomes the Need for Radiation.

The Addition of Rituximab to Dose-Adjusted EPOCH with HAART Suspension Is Highly Effective and Tolerable in AIDS-Related Lymphoma (ARL) and Allows the Delivery of Abbreviated Chemotherapy.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only